Paul Aisen

Feb 7, 2023 | alz-journals.onlinelibrary.wiley.com | Ronald Petersen |Paul Aisen |J. Scott Andrews |Alireza Atri

Abstract Alzheimer's disease (AD) clinical trials are designed and powered to detect the impact of a therapeutic intervention, and there has been considerable discussion on what constitutes a clinically meaningful change in those receiving treatment versus placebo. The pathology of AD is complex, beginning many years before clinical symptoms are detectable, with multiple potential opportunities for therapeutic engagement.